BBI Solutions wins Dx Creative Award for Morffi™ launch

BBI Solutions is pleased to announce that it has triumphed at the DxMA’s 2017 Dx Creative Awards, winning the New IVD Product Launch (less than $100m) category for the market release of its Morffi™ signal enhancement technology. The awards ceremony (held in New Orleans, USA, on the 30th of April) was an opportunity to celebrate the latest innovations in the diagnostics field ahead of the DxMA Global Marketing Summit on the 1st of May, where BBI’s Dr Neil Polwart was also presenting the company’s Novarum Dx mobile assay reader.

Officially unveiled at Medica 2016, the patent-pending Morffi signal enhancement technology (offered exclusively through BBI’s development service) can enhance the sensitivity of lateral flow immunoassays (LFIs), opening up new opportunities and allowing LFIs to compete with traditional lab-based testing platforms. The Medica launch included a ‘first to see’ breakfast seminar and white paper presentation, supported by an integrated marketing campaign and eye-catching exhibition stand, and garnered interest from across the diagnostics sector. “We are thrilled at this recognition of the hard work and dedication of our team,” commented Liam Taylor, Managing Director of BBI Solutions. “In this highly regulated industry, a sceptical audience is always a major challenge, but we’ve worked hard to support this innovative technology with robust and reliable data, offering a simple, swap-in technology which we hope will transform the future of diagnostics.”


Morffi is available as part of BBI’s research and development services through a licensing model. If you’re interested in developing a lateral flow device or redeveloping an assay, visit www.bbisolutions.com.

BBI Solutions

BBI Solutions is a leading manufacturer of biological reagents and finished test platforms for the in-vitro diagnostics market. BBI is a global business with manufacturing sites spanning three continents.

Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.

BBI Solutions offer lateral flow development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.

BBI Solutions is part of the BBI Group.



The Future of Pathology: Landmark initiative to spark conversation between pathology community and healthcare leaders

International panel of pathologists drive forward-thinking agenda on role of pathology in transformi...

Read More >

Abingdon Health Ltd (“Abingdon”) has announced its entry in the UK Parliamentary Review 2017 (“The Review”) has now been published.

While focusing on 12 key government policy areas, the Review, which is distributed to Policymakers i...

Read More >

CRYOcheck™ - Reducing Errors for 25 Years

For 25 years Precision BioLogic’s CRYOcheck™ range of fresh frozen plasma reagents, calibrators an...

Read More >

Improved Nucleic Acid Isolation

New QuickGene Range for DNA & RNA Extraction- Now with Automated Option

Read More >

SpeeDx and Thermo Fisher Scientific announce strategic partnership for FDA clearance of molecular diagnostic test

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement ...

Read More >

HORIBA Medical launches D-Dimer reagent for Yumizen G Haemostasis range

New Yumizen GDDi 2 (D-Dimer) reagent kit for DVT and Pulmonary Embolism diagnosis

Read More >